Article
Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses.
Hereditas - 23 Jul 2020
Zhou Huyue, Xiang Qiumei, Hu Changpeng, Zhang Jing, Zhang Qian, Zhang Rong
Abstract excerpt
BACKGROUND: Non-small cell lung cancer (NSCLC) is the major type of lung cancer with high morbidity and poor prognosis. Erlotinib, an inhibitor of epidermal growth factor receptor (EGFR), has been clinically applied for NSCLC treatment. Nevertheless, the erlotinib acquired resistance of NSCLC occurs inevitably in recent years. METHODS: Through analyzing two microarray datasets, erlotinib resistant NSCLC cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.